Peroxisome proliferator-activated receptors and inflammation: Take it to heart

Acta Physiologica

Volumn 191, Issue 3, 2007, Pages 171-188

  Smeets, P J H ^a   Planavila, A ^a   Van Der Vusse, G J ^a   Van Bilsen, M ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Hypertrophy; Infarction; Inflammation; Ischaemia reperfusion; NF B; PPAR

Indexed keywords

CIGLITAZONE; CLOFIBRATE; FENOFIBRATE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; TROGLITAZONE;

HEART CELL CULTURE; HEART HYPERTROPHY; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; INFLAMMATORY DISEASE; INFLAMMATORY INFILTRATE; LIPID METABOLISM; NONHUMAN; PRIORITY JOURNAL; PROTEIN VARIANT; REVIEW; THERAPY EFFECT; TRANSACTIVATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

CARDIOMEGALY; DOWN-REGULATION; HUMANS; INFLAMMATION; LIPID METABOLISM; MYOCARDIAL ISCHEMIA; MYOCARDIUM; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PROTEIN ISOFORMS; TRANS-ACTIVATION (GENETICS);

EID: 35248852831     PISSN: 17481708     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1748-1716.2007.01752.x     Document Type: Review

References (154)

1. Aasum, E., Hafstad, A.D., Severson, D.L. Larsen, T.S. 2003. Age-dependent changes in metabolism, contractile function, and ischemic sensitivity in hearts from db/db mice. Diabetes 52, 434 441.
2. Aberle, J., Hopfer, I., Beil, F.U. Seedorf, U. 2006. Association of the T + 294C polymorphism in PPAR delta with low HDL cholesterol and coronary heart disease risk in women. Int J Med Sci 3, 108 111.
3. Anversa, P., Cheng, W., Liu, Y., Leri, A., Redaelli, G. Kajstura, J. 1998. Apoptosis and myocardial infarction. Basic Res Cardiol 93 (Suppl. 3 8 12.
4. Arakawa, K., Ishihara, T., Aoto, M., Inamasu, M., Kitamura, K. Saito, A. 2004. An antidiabetic thiazolidinedione induces eccentric cardiac hypertrophy by cardiac volume overload in rats. Clin Exp Pharmacol Physiol 31, 8 13.
5. Asakawa, M., Takano, H., Nagai, T. et al. 2002. Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo. Circulation 105, 1240 1246.
6. Baldwin, A.S. Jr. 1996. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 14, 649 683.
7. Barger, P.M., Brandt, J.M., Leone, T.C., Weinheimer, C.J. Kelly, D.P. 2000. Deactivation of peroxisome proliferator-activated receptor-alpha during cardiac hypertrophic growth. J Clin Invest 105, 1723 1730.
8. Bell, D. McDermott, B.J. 2005. Effects of rosiglitazone and interactions with growth-regulating factors in ventricular cell hypertrophy. Eur J Pharmacol 508, 69 76.
9. van Bilsen, M., van der Vusse, G.J., Gilde, A.J., Lindhout, M. van der Lee, K.A. 2002. Peroxisome proliferator-activated receptors: lipid binding proteins controling gene expression. Mol Cell Biochem 239, 131 138.
10. van Bilsen, M., Smeets, P.J., Gilde, A.J. van der Vusse, G.J. 2004. Metabolic remodelling of the failing heart: the cardiac burn-out syndrome? Cardiovasc Res 61, 218 226.
11. Blanquart, C., Mansouri, R., Paumelle, R., Fruchart, J.C., Staels, B. Glineur, C. 2004. The protein kinase C signaling pathway regulates a molecular switch between transactivation and transrepression activity of the peroxisome proliferator-activated receptor alpha. Mol Endocrinol 18, 1906 1918.
12. Braissant, O., Foufelle, F., Scotto, C., Dauca, M. Wahli, W. 1996. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 137, 354 366.
13. Braunwald, E. Pfeffer, M.A. 1991. Ventricular enlargement and remodeling following acute myocardial infarction: mechanisms and management. Am J Cardiol 68, 1D 6D.
14. Bulhak, A.A., Sjoquist, P.O., Xu, C.B., Edvinsson, L. Pernow, J. 2006. Protection against myocardial ischaemia/reperfusion injury by PPAR-alpha activation is related to production of nitric oxide and endothelin-1. Basic Res Cardiol 101, 244 252.
15. Burkart, E.M., Courtois, M., Sambandam, N. Kelly, D.P. 2005. The nuclear receptor PPARbeta mediates novel effects on myocardial glucose metabolism (abstract). Circulation 112, U88.
16. Chao, T.H., Li, Y.H., Chen, J.H. et al. 2004. The 161TT genotype in the exon 6 of the peroxisome-proliferator-activated receptor gamma gene is associated with premature acute myocardial infarction and increased lipid peroxidation in habitual heavy smokers. Clin Sci (Lond) 107, 461 466.
17. Chawla, A., Barak, Y., Nagy, L., Liao, D., Tontonoz, P. Evans, R.M. 2001. PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med 7, 48 52.
18. Cheng, L., Ding, G., Qin, Q. et al. 2004. Cardiomyocyte-restricted peroxisome proliferator-activated receptor-delta deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy. Nat Med 10, 1245 1250.
19. Chinetti, G., Fruchart, J.C. Staels, B. 2000. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res 49, 497 505.
20. Chung, E.S., Packer, M., Lo, K.H., Fasanmade, A.A. Willerson, J.T. 2003. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 107, 3133 3140.
21. Clark, R.B. 2002. The role of PPARs in inflammation and immunity. J Leukoc Biol 71, 388 400.
22. Cook, W.S., Yeldandi, A.V., Rao, M.S., Hashimoto, T. Reddy, J.K. 2000. Less extrahepatic induction of fatty acid beta-oxidation enzymes by PPAR alpha. Biochem Biophys Res Commun 278, 250 257.
23. Delerive, P., De Bosscher, K., Besnard, S. et al. 1999a. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J Biol Chem 274, 32048 32054.
24. Delerive, P., Martin-Nizard, F., Chinetti, G. et al. 1999b. Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ Res 85, 394 402.
25. Delerive, P., De Bosscher, K., Vanden Berghe, W., Fruchart, J.C., Haegeman, G. Staels, B. 2002. DNA binding-independent induction of IkappaBalpha gene transcription by PPARalpha. Mol Endocrinol 16, 1029 1039.
26. Desvergne, B. Wahli, W. 1999. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 20, 649 688.
27. Devchand, P.R., Keller, H., Peters, J.M., Vazquez, M., Gonzalez, F.J. Wahli, W. 1996. The PPARalpha-leukotriene B4 pathway to inflammation control. Nature 384, 39 43.
28. Dewald, O., Sharma, S., Adrogue, J. et al. 2005. Downregulation of peroxisome proliferator-activated receptor-alpha gene expression in a mouse model of ischemic cardiomyopathy is dependent on reactive oxygen species and prevents lipotoxicity. Circulation 112, 407 415.
29. Diep, Q.N., Benkirane, K., Amiri, F., Cohn, J.S., Endemann, D. Schiffrin, E.L. 2004. PPARalpha activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II-infused rats. J Mol Cell Cardiol 36, 295 304.
30. Ding, G., Cheng, L., Qin, Q., Frontin, S. Yang, Q. 2006. PPARdelta modulates lipopolysaccharide-induced TNFalpha inflammation signaling in cultured cardiomyocytes. J Mol Cell Cardiol 40, 821 828.
31. Doney, A.S., Fischer, B., Leese, G., Morris, A.D. Palmer, C.N. 2004. Cardiovascular risk in type 2 diabetes is associated with variation at the PPARG locus: a Go-DARTS study. Arterioscler Thromb Vasc Biol 24, 2403 2407.
32. Doney, A.S., Fischer, B., Lee, S.P., Morris, A.D., Leese, G. Palmer, C.N. 2005. Association of common variation in the PPARA gene with incident myocardial infarction in individuals with type 2 diabetes: a Go-DARTS study. Nucl Recept 3, 4.
33. Dormandy, J.A., Charbonnel, B., Eckland, D.J. et al. 2005. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366, 1279 1289.
34. Duan, S.Z., Ivashchenko, C.Y., Russell, M.W., Milstone, D.S. Mortensen, R.M. 2005. Cardiomyocyte-specific knockout and agonist of peroxisome proliferator-activated receptor-gamma both induce cardiac hypertrophy in mice. Circ Res 97, 372 379.
35. Duhaney, T.A., Cui, L., Rude, M.K. et al. 2007. Peroxisome proliferator-activated receptor alpha-independent actions of fenofibrate exacerbates left ventricular dilation and fibrosis in chronic pressure overload. Hypertension 49, 1084 1094.
36. Edgley, A.J., Thalen, P.G., Dahllof, B., Lanne, B., Ljung, B. Oakes, N.D. 2006. PPARgamma agonist induced cardiac enlargement is associated with reduced fatty acid and increased glucose utilization in myocardium of Wistar rats. Eur J Pharmacol 538, 195 206.
37. Eefting, F., Rensing, B., Wigman, J. et al. 2004. Role of apoptosis in reperfusion injury. Cardiovasc Res 61, 414 426.
38. Feige, J.N., Gelman, L., Michalik, L., Desvergne, B. Wahli, W. 2006. From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. Prog Lipid Res 45, 120 159.
39. Finck, B.N. 2007. The PPAR regulatory system in cardiac physiology and disease. Cardiovasc Res 73, 269 277.
40. Finck, B.N., Lehman, J.J., Leone, T.C. et al. 2002. The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J Clin Invest 109, 121 130.
41. Flavell, D.M., Jamshidi, Y., Hawe, E. et al. 2002. Peroxisome proliferator-activated receptor alpha gene variants influence progression of coronary atherosclerosis and risk of coronary artery disease. Circulation 105, 1440 1445.
42. Frangogiannis, N.G., Smith, C.W. Entman, M.L. 2002. The inflammatory response in myocardial infarction. Cardiovasc Res 53, 31 47.
43. Frantz, S., Hu, K., Widder, J. et al. 2004. Peroxisome proliferator activated-receptor agonism and left ventricular remodeling in mice with chronic myocardial infarction. Br J Pharmacol 141, 9 14.
44. Frey, N. Olson, E.N. 2003. Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol 65, 45 79.
45. Fu, M., Zhang, J., Zhu, X. et al. 2001. Peroxisome proliferator-activated receptor gamma inhibits transforming growth factor beta-induced connective tissue growth factor expression in human aortic smooth muscle cells by interfering with Smad3. J Biol Chem 276, 45888 45894.
46. Gao, D.F., Niu, X.L., Hao, G.H. et al. 2007. Rosiglitazone inhibits angiotensin II-induced CTGF expression in vascular smooth muscle cells - role of PPAR-gamma in vascular fibrosis. Biochem Pharmacol 73, 185 197.
47. Geng, D.F., Wu, W., Jin, D.M., Wang, J.F. Wu, Y.M. 2006. Effect of peroxisome proliferator-activated receptor gamma ligand. Rosiglitazone on left ventricular remodeling in rats with myocardial infarction. Int J Cardiol 113, 86 91.
48. Ghosh, A.K., Bhattacharyya, S., Lakos, G., Chen, S.J., Mori, Y. Varga, J. 2004. Disruption of transforming growth factor beta signaling and profibrotic responses in normal skin fibroblasts by peroxisome proliferator-activated receptor gamma. Arthritis Rheum 50, 1305 1318.
49. Gilde, A.J., van der Lee, K.A., Willemsen, P.H. et al. 2003. Peroxisome proliferator-activated receptor (PPAR) alpha and PPARbeta/delta, but not PPARgamma, modulate the expression of genes involved in cardiac lipid metabolism. Circ Res 92, 518 524.
50. Gonon, A.T., Bulhak, A., Labruto, F., Sjoquist, P.O. Pernow, J. 2007. Cardioprotection mediated by rosiglitazone, a peroxisome proliferatoractivated receptor gamma ligand, in relation to nitric oxide. Basic Res Cardiol 102, 80 89.
51. Guo, B., Koya, D., Isono, M., Sugimoto, T., Kashiwagi, A. Haneda, M. 2004. Peroxisome proliferator-activated receptor-gamma ligands inhibit TGF-beta 1-induced fibronectin expression in glomerular mesangial cells. Diabetes 53, 200 208.
52. Gupta, S., Young, D. Sen, S. 2005. Inhibition of NF-kappaB induces regression of cardiac hypertrophy, independent of blood pressure control, in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 289, H20 H29.
53. Gurantz, D., Cowling, R.T., Varki, N., Frikovsky, E., Moore, C.D. Greenberg, B.H. 2005. IL-1beta and TNF-alpha upregulate angiotensin II type 1 (AT1) receptors on cardiac fibroblasts and are associated with increased AT1 density in the post-MI heart. J Mol Cell Cardiol 38, 505 515.
54. Hall, G., Hasday, J.D. Rogers, T.B. 2006. Regulating the regulator: NF-kappaB signaling in heart. J Mol Cell Cardiol 41, 580 591.
55. Hamano, T., Kobayashi, K., Sakairi, T., Hayashi, M. Mutai, M. 2001. Peroxisome proliferator-activated receptor alpha (PPAR alpha) agonist, WY-14,643, increased transcription of myosin light chain-2 in cardiomyocytes. J Toxicol Sci 26, 275 284.
56. Han, C., Demetris, A.J., Liu, Y., Shelhamer, J.H. Wu, T. 2004. Transforming growth factor-beta (TGF-beta) activates cytosolic phospholipase A2alpha (cPLA2alpha)-mediated prostaglandin E2 (PGE)2/EP1 and peroxisome proliferator-activated receptor-gamma (PPAR-gamma)/Smad signaling pathways in human liver cancer cells. A novel mechanism for subversion of TGF-beta-induced mitoinhibition. J Biol Chem 279, 44344 44354.
57. Hearse, D.J. 1990. Ischemia, reperfusion, and the determinants of tissue injury. Cardiovasc Drugs Ther 4 (Suppl. 4 767 776.
58. Higuchi, Y., Chan, T.O., Brown, M.A. et al. 2006. Cardioprotection afforded by NF-kappaB ablation is associated with activation of Akt in mice overexpressing TNF-alpha. Am J Physiol Heart Circ Physiol 290, H590 H598.
59. Hunter, J.J. Chien, K.R. 1999. Signaling pathways for cardiac hypertrophy and failure. N Engl J Med 341, 1276 1283.
60. Huss, J.M. Kelly, D.P. 2004. Nuclear receptor signaling and cardiac energetics. Circ Res 95, 568 578.
61. Ichihara, S., Obata, K., Yamada, Y. et al. 2006. Attenuation of cardiac dysfunction by a PPAR-alpha agonist is associated with down-regulation of redox-regulated transcription factors. J Mol Cell Cardiol 41, 318 329.
62. Iglarz, M., Touyz, R.M., Viel, E.C. et al. 2003. Peroxisome proliferator-activated receptor-alpha and receptor-gamma activators prevent cardiac fibrosis in mineralocorticoid-dependent hypertension. Hypertension 42, 737 743.
63. Irukayama-Tomobe, Y., Miyauchi, T., Sakai, S. et al. 2004. Endothelin-1-induced cardiac hypertrophy is inhibited by activation of peroxisome proliferator-activated receptor-alpha partly via blockade of c-Jun NH2-terminal kinase pathway. Circulation 109, 904 910.
64. Ito, H., Nakano, A., Kinoshita, M. Matsumori, A. 2003. Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates myocardial ischemia/reperfusion injury in a rat model. Lab Invest 83, 1715 1721.
65. Jamshidi, Y., Montgomery, H.E., Hense, H.W. et al. 2002. Peroxisome proliferator - activated receptor alpha gene regulates left ventricular growth in response to exercise and hypertension. Circulation 105, 950 955.
66. Ji, J.D., Kim, H.J., Rho, Y.H. et al. 2005. Inhibition of IL-10-induced STAT3 activation by 15-deoxy-Delta12,14-prostaglandin J2. Rheumatology (Oxford) 44, 983 988.
67. Kanda, H., Nohara, R., Hasegawa, K., Kishimoto, C. Sasayama, S. 2000. A nuclear complex containing PPARalpha/RXRalpha is markedly downregulated in the hypertrophied rat left ventricular myocardium with normal systolic function. Heart Vessels 15, 191 196.
68. Kantor, P.F., Dyck, J.R. Lopaschuk, G.D. 1999. Fatty acid oxidation in the reperfused ischemic heart. Am J Med Sci 318, 3 14.
69. Keech, A., Simes, R.J., Barter, P. et al. 2005. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366, 1849 1861.
70. Kelly, D., Campbell, J.I., King, T.P. et al. 2004. Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-gamma and RelA. Nat Immunol 5, 104 112.
71. Khandoudi, N., Delerive, P., Berrebi-Bertrand, I., Buckingham, R.E., Staels, B. Bril, A. 2002. Rosiglitazone, a peroxisome proliferator-activated receptor-gamma, inhibits the Jun NH(2)-terminal kinase/activating protein 1 pathway and protects the heart from ischemia/reperfusion injury. Diabetes 51, 1507 1514.
72. Kharroubi, I., Lee, C.H., Hekerman, P. et al. 2006. BCL-6: a possible missing link for anti-inflammatory PPAR-delta signalling in pancreatic beta cells. Diabetologia 49, 2350 2358.
73. Kim, H.J., Rho, Y.H., Choi, S.J. et al. 2005. 15-Deoxy-delta12,14-PGJ2 inhibits IL-6-induced Stat3 phosphorylation in lymphocytes. Exp Mol Med 37, 179 185.
74. Kintscher, U., Lyon, C., Wakino, S. et al. 2002. PPARalpha inhibits TGF-beta-induced beta5 integrin transcription in vascular smooth muscle cells by interacting with Smad4. Circ Res 91, e35 e44.
75. Krack, A., Sharma, R., Figulla, H.R. Anker, S.D. 2005. The importance of the gastrointestinal system in the pathogenesis of heart failure. Eur Heart J 26, 2368 2374.
76. Lahera, V., Goicoechea, M., de Vinuesa, S.G. et al. 2007. Endothelial dysfunction, oxidative stress and inflammation in atherosclerosis: beneficial effects of statins. Curr Med Chem 14, 243 248.
77. Lam, A. Lopaschuk, G.D. 2007. Anti-anginal effects of partial fatty acid oxidation inhibitors. Curr Opin Pharmacol 7, 179 185.
78. Lee, T.M. Chou, T.F. 2003. Troglitazone administration limits infarct size by reduced phosphorylation of canine myocardial connexin43 proteins. Am J Physiol Heart Circ Physiol 285, H1650 H1659.
79. Lee, C.H., Chawla, A., Urbiztondo, N., Liao, D., Boisvert, W.A. Evans, R.M. 2003. Transcriptional repression of atherogenic inflammation: modulation by PPARdelta. Science 302, 453 457.
80. Levine, B., Kalman, J., Mayer, L., Fillit, H.M. Packer, M. 1990. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 323, 236 241.
81. Li, C., Browder, W. Kao, R.L. 1999. Early activation of transcription factor NF-kappaB during ischemia in perfused rat heart. Am J Physiol 276, H543 H552.
82. Li, Y., Ha, T., Gao, X. et al. 2004. NF-kappaB activation is required for the development of cardiac hypertrophy in vivo. Am J Physiol Heart Circ Physiol 287, H1712 H1720.
83. Li, L., Cheng, L.X., Nsenga, R., He, M.A. Wu, T.C. 2006. Association between Pro12Ala polymorphism of peroxisome proliferator-activated receptor-gamma 2 and myocardial infarction in the Chinese Han population. Clin Cardiol 29, 300 304.
84. Li, R., Zheng, W., Pi, R. et al. 2007. Activation of peroxisome proliferator-activated receptor-alpha prevents glycogen synthase 3beta phosphorylation and inhibits cardiac hypertrophy. FEBS Lett 581, 3311 3316.
85. Liang, F., Wang, F., Zhang, S. Gardner, D.G. 2003. Peroxisome proliferator activated receptor (PPAR)alpha agonists inhibit hypertrophy of neonatal rat cardiac myocytes. Endocrinology 144, 4187 4194.
86. Liu, H.R., Tao, L., Gao, E. et al. 2004. Anti-apoptotic effects of rosiglitazone in hypercholesterolemic rabbits subjected to myocardial ischemia and reperfusion. Cardiovasc Res 62, 135 144.
87. Lygate, C.A., Hulbert, K., Monfared, M., Cole, M.A., Clarke, K. Neubauer, S. 2003. The PPARgamma-activator rosiglitazone does not alter remodeling but increases mortality in rats post-myocardial infarction. Cardiovasc Res 58, 632 637.
88. Mamdani, M., Juurlink, D.N., Lee, D.S. et al. 2004. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet 363, 1751 1756.
89. Mann, D.L., McMurray, J.J., Packer, M. et al. 2004. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 109, 1594 1602.
90. Massague, J. 2000. How cells read TGF-beta signals. Nat Rev Mol Cell Biol 1, 169 178.
91. Molavi, B., Chen, J. Mehta, J.L. 2006. Cardioprotective effects of rosiglitazone are associated with selective overexpression of type 2 angiotensin receptors and inhibition of p42/44 MAPK. Am J Physiol Heart Circ Physiol 291, H687 H693.
92. Morgan, E.E., Rennison, J.H., Young, M.E. et al. 2006. Effects of chronic activation of peroxisome proliferator-activated receptor-alpha or high-fat feeding in a rat infarct model of heart failure. Am J Physiol Heart Circ Physiol 290, H1899 H1904.
93. Morimura, K., Cheung, C., Ward, J.M., Reddy, J.K. Gonzalez, F.J. 2006. Differential susceptibility of mice humanized for peroxisome proliferator-activated receptor alpha to Wy-14,643-induced liver tumorigenesis. Carcinogenesis 27, 1074 1080.
94. Morishima, A., Ohkubo, N., Maeda, N., Miki, T. Mitsuda, N. 2003. NFkappaB regulates plasma apolipoprotein A-I and high density lipoprotein cholesterol through inhibition of peroxisome proliferator-activated receptor alpha. J Biol Chem 278, 38188 38193.
95. Nissen, S.E. Wolski, K. 2007. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356, 2457 2471.
96. Nissen, S.E., Wolski, K. Topol, E.J. 2005. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA 294, 2581 2586.
97. Nuclear Receptors Nomenclature Committee 1999. A unified nomenclature system for the nuclear receptor superfamily. Cell 97, 161 163.
98. Ogata, T., Miyauchi, T., Sakai, S., Irukayama-Tomobe, Y., Goto, K. Yamaguchi, I. 2002. Stimulation of peroxisome-proliferator-activated receptor alpha (PPAR alpha) attenuates cardiac fibrosis and endothelin-1 production in pressure-overloaded rat hearts. Clin Sci (Lond) 103 (Suppl. 48 284S 288S.
99. Onai, Y., Suzuki, J., Kakuta, T. et al. 2004. Inhibition of IkappaB phosphorylation in cardiomyocytes attenuates myocardial ischemia/reperfusion injury. Cardiovasc Res 63, 51 59.
100. Osorio, J.C., Stanley, W.C., Linke, A. et al. 2002. Impaired myocardial fatty acid oxidation and reduced protein expression of retinoid X receptor-alpha in pacing-induced heart failure. Circulation 106, 606 612.
101. Palmer, J.N., Hartogensis, W.E., Patten, M., Fortuin, F.D. Long, C.S. 1995. Interleukin-1 beta induces cardiac myocyte growth but inhibits cardiac fibroblast proliferation in culture. J Clin Invest 95, 2555 2564.
102. Panagia, M., Gibbons, G.F., Radda, G.K. Clarke, K. 2005. PPAR-alpha activation required for decreased glucose uptake and increased susceptibility to injury during ischemia. Am J Physiol Heart Circ Physiol 288, H2677 H2683.
103. Park, E.J., Park, S.Y., Joe, E.H. Jou, I. 2003. 15d-PGJ2 and rosiglitazone suppress Janus kinase-STAT inflammatory signaling through induction of suppressor of cytokine signaling 1 (SOCS1) and SOCS3 in glia. J Biol Chem 278, 14747 14752.
104. Pascual, G., Fong, A.L., Ogawa, S. et al. 2005. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature 437, 759 763.
105. Pischon, T., Pai, J.K., Manson, J.E. et al. 2005. Peroxisome proliferator-activated receptor-gamma2 P12A polymorphism and risk of coronary heart disease in US men and women. Arterioscler Thromb Vasc Biol 25, 1654 1658.
106. Planavila, A., Laguna, J.C. Vazquez-Carrera, M. 2005a. Nuclear factor-kappaB activation leads to down-regulation of fatty acid oxidation during cardiac hypertrophy. J Biol Chem 280, 17464 17471.
107. Planavila, A., Rodriguez-Calvo, R., Jove, M. et al. 2005b. Peroxisome proliferator-activated receptor beta/delta activation inhibits hypertrophy in neonatal rat cardiomyocytes. Cardiovasc Res 65, 832 841.
108. Porter, K.E., Turner, N.A., O'Regan, D.J. Ball, S.G. 2004. Tumor necrosis factor alpha induces human atrial myofibroblast proliferation, invasion and MMP-9 secretion: inhibition by simvastatin. Cardiovasc Res 64, 507 515.
109. Puigserver, P. Spiegelman, B.M. 2003. Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator. Endocr Rev 24, 78 90.
110. Purcell, N.H., Tang, G., Yu, C., Mercurio, F., DiDonato, J.A. Lin, A. 2001. Activation of NF-kappa B is required for hypertrophic growth of primary rat neonatal ventricular cardiomyocytes. Proc Natl Acad Sci USA 98, 6668 6673.
111. Razeghi, P., Young, M.E., Abbasi, S. Taegtmeyer, H. 2001. Hypoxia in vivo decreases peroxisome proliferator-activated receptor alpha-regulated gene expression in rat heart. Biochem Biophys Res Commun 287, 5 10.
112. Razeghi, P., Wang, M.E., Youker, K.A., Golfman, L., Stepkowski, S. Taegtmeyer, H. 2007. Lack of NF-kappaB1 (p105/p50) attenuates unloading-induced downregulation of PPARalpha and PPARalpha-regulated gene expression in rodent heart. Cardiovasc Res 74, 133 139.
113. Rose, M., Balakumar, P. Singh, M. 2007. Ameliorative effect of combination of fenofibrate and rosiglitazone in pressure overload-induced cardiac hypertrophy in rats. Pharmacology 80, 177 184.
114. Sack, M.N., Rader, T.A., Park, S., Bastin, J., McCune, S.A. Kelly, D.P. 1996. Fatty acid oxidation enzyme gene expression is downregulated in the failing heart. Circulation 94, 2837 2842.
115. Sakai, S., Miyauchi, T., Irukayama-Tomobe, Y., Ogata, T., Goto, K. Yamaguchi, I. 2002. Peroxisome proliferator-activated receptor-gamma activators inhibit endothelin-1-related cardiac hypertrophy in rats. Clin Sci (Lond) 103 (Suppl. 48 16S 20S.
116. Sambandam, N., Morabito, D., Wagg, C., Finck, B.N., Kelly, D.P. Lopaschuk, G.D. 2006. Chronic activation of PPARalpha is detrimental to cardiac recovery after ischemia. Am J Physiol Heart Circ Physiol 290, H87 H95.
117. Seta, Y., Shan, K., Bozkurt, B., Oral, H. Mann, D.L. 1996. Basic mechanisms in heart failure: the cytokine hypothesis. J Card Fail 2, 243 249.
118. Shimabukuro, M., Higa, S., Shinzato, T., Nagamine, F., Komiya, I. Takasu, N. 1996. Cardioprotective effects of troglitazone in streptozotocin-induced diabetic rats. Metabolism 45, 1168 1173.
119. Shiomi, T., Tsutsui, H., Hayashidani, S. et al. 2002. Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 106, 3126 3132.
120. Shipley, J.M. Waxman, D.J. 2003. Down-regulation of STAT5b transcriptional activity by ligand-activated peroxisome proliferator-activated receptor (PPAR) alpha and PPARgamma. Mol Pharmacol 64, 355 364.
121. Sidell, R.J., Cole, M.A., Draper, N.J., Desrois, M., Buckingham, R.E. Clarke, K. 2002. Thiazolidinedione treatment normalizes insulin resistance and ischemic injury in the zucker Fatty rat heart. Diabetes 51, 1110 1117.
122. Sivarajah, A., McDonald, M.C. Thiemermann, C. 2005. The cardioprotective effects of preconditioning with endotoxin, but not ischemia, are abolished by a peroxisome proliferator-activated receptor-gamma antagonist. J Pharmacol Exp Ther 313, 896 901.
123. Skogsberg, J., McMahon, A.D., Karpe, F., Hamsten, A., Packard, C.J. Ehrenborg, E. 2003. Peroxisome proliferator activated receptor delta genotype in relation to cardiovascular risk factors and risk of coronary heart disease in hypercholesterolaemic men. J Intern Med 254, 597 604.
124. Solomon, S.D., Pfeffer, M.A., McMurray, J.J. et al. 2006. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation 114, 1028 1035.
125. Stanley, T.B., Leesnitzer, L.M., Montana, V.G. et al. 2003. Subtype specific effects of peroxisome proliferator-activated receptor ligands on corepressor affinity. Biochemistry 42, 9278 9287.
126. Stanley, W.C., Recchia, F.A. Lopaschuk, G.D. 2005. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev 85, 1093 1129.
127. Subbaramaiah, K., Lin, D.T., Hart, J.C. Dannenberg, A.J. 2001. Peroxisome proliferator-activated receptor gamma ligands suppress the transcriptional activation of cyclooxygenase-2. Evidence for involvement of activator protein-1 and CREB-binding protein/p300. J Biol Chem 276, 12440 12448.
128. Tabernero, A., Schoonjans, K., Jesel, L., Carpusca, I., Auwerx, J. Andriantsitohaina, R. 2002. Activation of the peroxisome proliferator-activated receptor alpha protects against myocardial ischaemic injury and improves endothelial vasodilatation. BMC Pharmacol 2, 10.
129. Tan, N.S., Michalik, L., Di-Poi, N. et al. 2004. Essential role of Smad3 in the inhibition of inflammation-induced PPARbeta/delta expression. EMBO J 23, 4211 4221.
130. Terrell, A.M., Crisostomo, P.R., Wairiuko, G.M., Wang, M., Morrell, E.D. Meldrum, D.R. 2006. Jak/STAT/SOCS signaling circuits and associated cytokine-mediated inflammation and hypertrophy in the heart. Shock 26, 226 234.
131. Teunissen, B.E., Smeets, P.J., Willemsen, P.H., De Windt, L.J., Van der Vusse, G.J. Van Bilsen, M. 2007. Activation of PPARdelta inhibits cardiac fibroblast proliferation and the transdifferentiation into myofibroblasts. Cardiovasc Res 75, 519 529.
132. Thaik, C.M., Calderone, A., Takahashi, N. Colucci, W.S. 1995. Interleukin-1 beta modulates the growth and phenotype of neonatal rat cardiac myocytes. J Clin Invest 96, 1093 1099.
133. Tian, Q., Grzemski, F.A., Panagiotopoulos, S. Ahokas, J.T. 2006. Peroxisome proliferator-activated receptor alpha agonist, clofibrate, has profound influence on myocardial fatty acid composition. Chem Biol Interact 160, 241 251.
134. Trifilieff, A., Bench, A., Hanley, M., Bayley, D., Campbell, E. Whittaker, P. 2003. PPAR-alpha and -gamma but not -delta agonists inhibit airway inflammation in a murine model of asthma: in vitro evidence for an NF-kappaB-independent effect. Br J Pharmacol 139, 163 171.
135. van der Vusse, G.J., Glatz, J.F., Stam, H.C. Reneman, R.S. 1992. Fatty acid homeostasis in the normoxic and ischemic heart. Physiol Rev 72, 881 940.
136. Wang, X.L., Oosterhof, J. Duarte, N. 1999. Peroxisome proliferator-activated receptor gamma C161 - >T polymorphism and coronary artery disease. Cardiovasc Res 44, 588 594.
137. Wayman, N.S., Ellis, B.L. Thiemermann, C. 2002a. Ligands of the peroxisome proliferator-activated receptor-PPAR-a reduce myocardial infarct size. Med Sci Monit 8, BR243 BR247.
138. Wayman, N.S., Hattori, Y., McDonald, M.C. et al. 2002b. Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size. FASEB J 16, 1027 1040.
139. Wu, L., Wang, R., De Champlain, J. Wilson, T.W. 2004. Beneficial and deleterious effects of rosiglitazone on hypertension development in spontaneously hypertensive rats. Am J Hypertens 17, 749 756.
140. Wynne, A.M., Mocanu, M.M. Yellon, D.M. 2005. Pioglitazone mimics preconditioning in the isolated perfused rat heart: a role for the prosurvival kinases PI3K and P42/44MAPK. J Cardiovasc Pharmacol 46, 817 822.
141. Xu, Y., Lu, L., Greyson, C. et al. 2003. Deleterious effects of acute treatment with a peroxisome proliferator-activated receptor-gamma activator in myocardial ischemia and reperfusion in pigs. Diabetes 52, 1187 1194.
142. Xu, Y., Gen, M., Lu, L. et al. 2005. PPAR-gamma activation fails to provide myocardial protection in ischemia and reperfusion in pigs. Am J Physiol Heart Circ Physiol 288, H1314 H1323.
143. Xu, Y., Lu, L., Greyson, C. et al. 2006. The PPAR-alpha activator fenofibrate fails to provide myocardial protection in ischemia and reperfusion in pigs. Am J Physiol Heart Circ Physiol 290, H1798 H1807.
144. Yamamoto, K., Ohki, R., Lee, R.T., Ikeda, U. Shimada, K. 2001. Peroxisome proliferator-activated receptor gamma activators inhibit cardiac hypertrophy in cardiac myocytes. Circulation 104, 1670 1675.
145. Yeh, C.H., Chen, T.P., Lee, C.H., Wu, Y.C., Lin, Y.M. Lin, P.J. 2006. Cardiomyocytic apoptosis following global cardiac ischemia and reperfusion can be attenuated by peroxisome proliferator-activated receptor alpha but not gamma activators. Shock 26, 262 270.
146. Yndestad, A., Damas, J.K., Oie, E., Ueland, T., Gullestad, L. Aukrust, P. 2006. Systemic inflammation in heart failure - the whys and wherefores. Heart Fail Rev 11, 83 92.
147. Yokoyama, T., Nakano, M., Bednarczyk, J.L., McIntyre, B.W., Entman, M. Mann, D.L. 1997. Tumor necrosis factor-alpha provokes a hypertrophic growth response in adult cardiac myocytes. Circulation 95, 1247 1252.
148. Young, M.E., Laws, F.A., Goodwin, G.W. Taegtmeyer, H. 2001. Reactivation of peroxisome proliferator-activated receptor alpha is associated with contractile dysfunction in hypertrophied rat heart. J Biol Chem 276, 44390 44395.
149. Yue, T.L., Chen, J., Bao, W. et al. 2001. In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. Circulation 104, 2588 2594.
150. Yue, T.L., Bao, W., Jucker, B.M. et al. 2003. Activation of peroxisome proliferator-activated receptor-alpha protects the heart from ischemia/reperfusion injury. Circulation 108, 2393 2399.
151. Zhang, H., Zhang, A., Kohan, D.E., Nelson, R.D., Gonzalez, F.J. Yang, T. 2005. Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention. Proc Natl Acad Sci USA 102, 9406 9411.
152. Zhou, Y.C. Waxman, D.J. 1999. STAT5b down-regulates peroxisome proliferator-activated receptor alpha transcription by inhibition of ligand-independent activation function region-1 trans-activation domain. J Biol Chem 274, 29874 29882.
153. Zhu, P., Lu, L., Xu, Y. Schwartz, G.G. 2000. Troglitazone improves recovery of left ventricular function after regional ischemia in pigs. Circulation 101, 1165 1171.
154. Zingarelli, B., Hake, P.W., Mangeshkar, P. et al. 2007. Diverse cardioprotective signaling mechanisms of peroxisome proliferator-activated receptor-gamma ligands, 15-deoxy-delta12,14-prostaglandin J2 and ciglitazone, in